Page last updated: 2024-12-07

embusartan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID133000
CHEMBL ID1742441
SCHEMBL ID167147
MeSH IDM0283274

Synonyms (20)

Synonym
methyl 6-butyl-1-((3-fluoro-2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1,2-dihydro-2-oxo-4-pyridinecarboxylate
4my73645xa ,
unii-4my73645xa
4-pyridinecarboxylic acid, 6-butyl-1-((3-fluoro-2'-(1h-tetrzol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1,2-dihydro-2-oxo-, methyl ester
methyl 6-butyl-1-(2-fluoro-4-(o-1h-tetrazol-5-ylphenyl)benzyl)-1,2-dihydro-2-oxoisonicotinate
4-pyridinecarboxylic acid, 6-butyl-1-((3-fluoro-2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1,2-dihydro-2-oxo-, methyl ester
methyl 6-butyl-1-((3-fluoro-2'-(1h-tetrzol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1,2-dihydro-2-oxo-4-pyridinecarboxylate
embusartan [inn]
embusartan
L010991
methyl 2-butyl-1-[[2-fluoro-4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-6-oxopyridine-4-carboxylate
156001-18-2
bay-10-6734
6-n-butyl-4-methoxycarbonyl-2-oxo-1-((2'-(1h-tetrazol-5-yl)-3-fluorobiphenyl-4-yl)methyl)-1,2-dihydropyridine
CHEMBL1742441
SCHEMBL167147
embusartan [who-dd]
DTXSID50166029
Q27260170
AKOS040751675

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic properties of a new angiotensin II receptor antagonist (BAY 10-6734) in humans were to be quantitatively characterized from the rightward shifts of the agonist dose-response curves after administration of different doses of the antagonist."( Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Belz, GG; Breithaupt-Grögler, K; Butzer, R; Herrmann, V; Malerczyk, C; Stass, H; Wensing, G, 1997
)
0.3
" Pharmacodynamic (3."( Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Belz, GG; Breithaupt-Grögler, K; Butzer, R; Herrmann, V; Malerczyk, C; Stass, H; Wensing, G, 1997
)
0.3
" The time kinetics of the pharmacodynamic effect, derived from the decay of DR-1 values, as well as the doubling time of the apparent Ki values well agreed with the pharmacokinetic half-life."( Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Belz, GG; Breithaupt-Grögler, K; Butzer, R; Herrmann, V; Malerczyk, C; Stass, H; Wensing, G, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
"The pharmacodynamic properties of a new angiotensin II receptor antagonist (BAY 10-6734) in humans were to be quantitatively characterized from the rightward shifts of the agonist dose-response curves after administration of different doses of the antagonist."( Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Belz, GG; Breithaupt-Grögler, K; Butzer, R; Herrmann, V; Malerczyk, C; Stass, H; Wensing, G, 1997
)
0.3
" Before and up to 23 h post dosing (p."( Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Belz, GG; Breithaupt-Grögler, K; Butzer, R; Herrmann, V; Malerczyk, C; Stass, H; Wensing, G, 1997
)
0.3
" To investigate blockade of postsynaptic AT1 receptors, we studied the effect of the AT1 antagonists on dose-response curves elicited by exogenous Ang II."( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001
)
0.5
" Interestingly, the greatest doses of the AT1 antagonists caused less than maximal reduction in the stimulation-induced increase in DBP, resulting in a U-shaped dose-response relationship."( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (62.50)18.2507
2000's3 (37.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]